← Back to Clinical Trials
Recruiting NCT01087333

NCT01087333 Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01087333
Status Recruiting
Phase
Sponsor National Cancer Institute (NCI)
Condition Hairy Cell Leukemia (HCL)
Study Type OBSERVATIONAL
Enrollment 1,263 participants
Start Date 2010-03-02
Primary Completion

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,263 participants in total. It began in 2010-03-02.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell. Objectives: \- To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia. Eligibility: \- Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers. Design: * Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples. * No treatment will be given as part of this protocol.

Eligibility Criteria

* INCLUSION CRITERIA: All participants * 18 years of age and older * Desire of the individual to submit data and samples for research * Ability to understand and the willingness to sign a written informed consent document. Individuals with cancer -Participants may have a diagnosis of hematologic malignancy or solid tumor. These participants would not be excluded if they were in long-term complete remission. Normal donors (Individuals without cancer) -Individuals must not have a current or prior diagnosis of a hematologic malignancy or solid tumor. EXCLUSION CRITERIA: All participants -Known pregnancy at enrollment. NOTE: A pregnancy test will be required in individuals on study prior to any procedure done for research purposes that is greater than minimal risk.

Contact & Investigator

Central Contact

Julie C Feurtado, R.N.

✉ julie.feurtado@nih.gov

📞 (301) 480-6186

Principal Investigator

Robert J Kreitman, M.D.

PRINCIPAL INVESTIGATOR

National Cancer Institute (NCI)

Frequently Asked Questions

Who can join the NCT01087333 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Hairy Cell Leukemia (HCL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01087333 currently recruiting?

Yes, NCT01087333 is actively recruiting participants. Contact the research team at julie.feurtado@nih.gov for enrollment information.

Where is the NCT01087333 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT01087333 clinical trial?

NCT01087333 is sponsored by National Cancer Institute (NCI). The principal investigator is Robert J Kreitman, M.D. at National Cancer Institute (NCI). The trial plans to enroll 1,263 participants.

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology